

PATENT
Customer Number: 22,852
Attorney Docket No. 09388.0010-01000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of:)
Amy ARROW et al.) Group Art Unit: 1635
Application No.: 09/211,794) Examiner: Janet L. Epps Ford
Filed: December 15, 1998) Confirmation No. 9449
For: THREE COMPONENT)
CHIMERIC ANTISENSE)
OLIGONUCLEOTIDES)

OFFICE OF PETITIONS

JUL 09 2004

HAND CARRY TO: Mail Stop 313(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the attention of the Examiner the documents listed on the attached Form PTO 1449. This Information Disclosure Statement ("Statement") is being filed, to the undersigned's knowledge, before the mailing date of a first Office Action on the merits after a Request for Continued Examination (RCE), which is filed concurrently herewith.

Copies of the listed documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: July 8, 2004

By: 
Michael R. Albrecht
Reg. No. 54,956
Customer No. 22,852

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09388.0010-01000	Appln. No.	09/211,794	RECEIVED
Applicant	Amy ARROW et al.			JUL 09 2004
Filing Date	December 15, 1998	Group:	1635	OFFICE OF PETITIONS

U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	WO 89/05358	06/15/1989	PCT			
	WO 93/19203	09/30/1993	PCT			
	WO 94/02498	02/03/1994	PCT			
	WO 94/08053	04/14/1994	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Monia et al., "Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression," <i>The Journal of Biological Chemistry</i> , 268(19):14514-14522 (1993).
	Agrawal, "Antisense oligonucleotides as antiviral agents," <i>Trends in Biotechnology</i> , 10(5): 152-158 (1992).
	Supplementary European Search Report for Application No. EP 97 94 3607, mailed March 31, 2004.

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce
---------------	---